Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ravulizumab in HSCT-Associated Thrombotic Microangiopathy in Pediatric Patients
2020-000761-16Phase 3
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in transplant-associated thrombotic microangiopathy (TA-TMA) and thrombotic microangiopathies (TMA), sponsored by Alexion Pharmaceuticals. Primary endpoint: TMA response.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2020-000761-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000761-16.